Perosphere announced that the Food and Drug Administration (FDA) has granted Fast Track designation to PER977, an anticoagulant reversal agent.
PER977 is a small synthetic water-soluble new molecular entity that directly combines with new oral anticoagulants (eg, direct Xa- and IIa- inhibitors), fondaparinux, low molecular weight heparins and unfractionated heparins thus enabling rapid re-establishment of a normal blood coagulation state. This reversal effect is due to direct binding to the anticoagulant molecule with no binding to blood coagulation factors or to other proteins in the blood.
RELATED: BI Requesting Accelerated Approval for Pradaxa Reversal Agent
Currently, PER977 is undergoing clinical development as a sterile, intravenous injection.
For more information visit Perosphere.com.